RECRO PHARMA INC (REPH)

Company Profile

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The company is headquartered in Exton, Pennsylvania and currently employs 258 full-time employees. The company went IPO on 2014-03-07. The firm is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. The company also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. The company operates in one segment. The company provides support services capabilities, which includes preparation of clinical trial supplies, specialized services for the development and Good Manufacturing Practices (GMP) of products, as well as aseptic fill/finish and lyophilization. The firm develops and/or manufactures various products, such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM and Verapamil SR. Its manufacturing and development capabilities include formulation, product development through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms.

Company Info

RECRO PHARMA INC

1 E. Uwchlan Ave, Suite 112

Exton PENNSYLVANIA 19341

P: 17705348239.0

CEO: J. David Enloe

Employees: 258

Website: https://ir.recropharma.com/